Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kazal-type serine protease inhibitor domain-containing protein 1 (KAZALD1)
- Target
- KAZALD1
- Molecular classification
- Serine protease inhibitor, Insulin-like growth factor binding protein family (IGFBP superfamily), Secreted protein, Contains Kazal-type domain, immunoglobulin-like domain, follistatin-like domain
01
Overview
Kazal-type serine protease inhibitor domain-containing protein 1 (KAZALD1) is a secreted protein with a Kazal-type serine protease inhibitor domain, an immunoglobulin-like domain, and an insulin-like growth factor-binding domain. It is involved in bone development and regeneration, likely supporting osteoblast proliferation and matrix assembly. KAZALD1 is hypomethylated and overexpressed in high-grade gliomas, suggesting a role in tumor cell proliferation. It belongs to the IGFBP superfamily and is related to extracellular matrix organization and growth factor regulation
- Other names
- FKSG28FKSG40UNQ2945/PRO21184BONO1IGFBP-rP10IGFBP-related protein 10bone- and odontoblast-expressed gene 1novel Kazal-type serine protease inhibitor domain and immunoglobulin domain containing protein
02
Mechanism of action
Not established for any drugs; inferred as "serine protease inhibition" and "modulation of IGF activity" based on domain structure
03
Biological functions
Bone developmentBone regenerationOsteoblast proliferationExtracellular matrix organizationInsulin-like growth factor binding
04
Disease associations
Cancer (overexpressed/hypomethylated in high-grade glioma, associated with cell proliferation and poor survival)Multiple congenital anomalies (associated with a deletion in its locus)Spinal canal neoplasms
05
Biomarkers
Hypomethylation and overexpression as biomarkers for high-grade glioma prognosis
Beyond the preview
Go deeper on Kazal-type serine protease inhibitor domain-containing protein 1 (KAZALD1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kazal-type serine protease inhibitor domain-containing protein 1 (KAZALD1).